

July 12, 2023

To  The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> Floor, Dalal Street Mumbai – 400001  <b>Code: 540222</b>	To  The Listing Department National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051  <b>Code: LAURUSLABS</b>
--	--

**Sub: Update on Investment in M/s. Immunoadoptive Cell Therapy Private Limited**

**Ref: Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 dated May 31, 2023**

Dear Sirs,

This has reference to our disclosure dated May 31, 2023 regarding the signing of definitive agreements to acquire additional stake of 7.24% (on fully diluted basis) in Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company for a cash consideration of Rs. 80 Crores.

In this regard, we wish to update that the Company has paid the subscription amount of Rs. 48.01 Crores (Rupees Forty Eight Crores and One Lakhs only) as “Tranche 1 Subscription Amount”.

This is for your information and record.

Yours faithfully,  
**For Laurus Labs Limited**

**G. Venkateswar Reddy**  
Company Secretary